Core Insights - Processa Pharmaceuticals, Inc. has secured a strategic investment and is exploring corporate cryptocurrency treasury strategies to enhance financial flexibility and long-term value creation [1][2][4] Group 1: Strategic Financial Initiatives - The company believes that engaging with emerging financial technologies, including select cryptocurrencies, may diversify its capital base and enhance financial flexibility [2][3] - Processa is committed to compliance with regulatory standards while recognizing the potential of blockchain-based assets to fund clinical development programs, thereby reducing dilution for existing shareholders [3][4] Group 2: Corporate Development and Partnerships - The company is focused on long-term value creation, transparency, and responsible stewardship of investor capital, as stated by CEO George Ng [4] - Processa has engaged LifeSci Capital, LLC as an advisor for implementing its cryptocurrency treasury strategy [4] Group 3: Company Overview - Processa Pharmaceuticals is a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies aimed at improving safety and efficacy for cancer patients [5] - The company's strategy involves modifying existing FDA-approved oncology therapies to enhance their effectiveness while maintaining their cancer-killing mechanisms [5]

VERO BEACH, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies for cancer patients, today announced that it has secured a strategic investment and that it is evaluating corporate cryptocurrency treasury strategies as part of its broader financial and growth objectives. We believe that strategic engagement with emerging financial technologies, including select cryptocurrencies with ...

Core Insights - Processa Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing next-generation cancer therapies with enhanced efficacy and safety [1][5] - Dr. David Young, the Founder and President of Research & Development, will present at the World Orphan Drug Congress USA 2025 [1][2] - The presentation will discuss the application of FDA's Project Optimus principles to improve drug approval processes for rare oncology and non-oncology diseases [3] Company Overview - Processa's strategy involves modifying existing FDA-approved oncology therapies to enhance their metabolism and distribution while preserving their cancer-killing mechanisms [5] - The company aims to develop more effective therapy options with improved tolerability for cancer patients through a regulatory science approach [5] Event Details - Dr. Young's presentation is scheduled for April 24, 2025, at 2:00 p.m. Eastern Time at the Boston Convention & Exhibition Center [2] - The focus of the presentation will be on optimizing dose determination to balance efficacy and safety in drug development [3]

Core Insights - Processa Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing next-generation cancer therapies with enhanced efficacy and safety [1][5] - Dr. David Young, the Founder and President of Research & Development, will present at the World Orphan Drug Congress USA 2025, discussing FDA's Project Optimus principles [2][3] Company Overview - Processa's strategy involves modifying existing FDA-approved oncology therapies to improve their metabolism and distribution while retaining their cancer-killing mechanisms [5] - The company aims to develop more effective therapy options with better tolerability for cancer patients through an efficient regulatory path [5] Presentation Details - Dr. Young's presentation is titled "Applying Principles of FDA's Project Optimus to Oncology and Non-Oncology Rare Diseases" and is scheduled for April 24, 2025 [2][3] - The presentation will focus on optimizing drug dosing to enhance the balance of efficacy and safety for rare oncology and non-oncology diseases [3]